Source-grounded facts extracted from Metagenomi Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Brian C. Thomas resigned as director at Metagenomi Therapeutics, Inc..
“On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.”
Metagenomi Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 18,483,295 51,847 581,065”
Metagenomi Therapeutics, Inc. shareholders approved Election of Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II Directors at the 2026-06-09 meeting.
“Proposal 1 - Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until the Company’s 2029 annual meeting of stockholders, and until their respective successor shall have been duly elected and qualified, or until their earlier death, resignation or removal, based on the following votes: Class II Director Nominee For Withheld Broker Non-Votes Juergen Eckhardt, M.D., M.B.A. 7,296,718 1,436,882 10,382,607 Eric Bjerkholt, M.B.A. 8,251,289 482,311 10,382,607”
Metagenomi Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“today reported financial results for the first quarter ended March 31, 2026, and provided business updates.”
Metagenomi Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 11, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and additional business updates.”
Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.
“On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates.”
Metagenomi Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2026-01-12).
“the Company’s Board also amended and restated its Amended and Restated Bylaws (as amended, the “Second Amended and Restated Bylaws”), effective on January 12, 2026, solely to reflect the Name Change.”
Metagenomi Therapeutics, Inc.: Amended certificate of incorporation to change company name from Metagenomi, Inc. to Metagenomi Therapeutics, Inc (effective 2026-01-12).
“filed a certificate of amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), solely to change the Company’s name from “Metagenomi, Inc.” to “Metagenomi Therapeutics, Inc.” (the “Name Change”), which became effective at 12:01 a.m. Pacific Time on January 12, 2026.”
Eric Bjerkholt was appointed as Class II Director at Metagenomi Therapeutics, Inc..
“appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025”
Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.
“announced its financial results for the quarter ended March 31, 2024”
Metagenomi Therapeutics, Inc. terminated Strategic Collaboration and License Agreement with ModernaTX, Inc. (effective 2024-04-26).
“On April 26, 2024 (the “Termination Date”), Metagenomi, Inc. (the “Company”) and ModernaTX, Inc. (“Moderna”) mutually terminated the Strategic Collaboration and License Agreement dated October 29, 2021 (the “Collaboration Agreement”) by and between the Company and Moderna.”
Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.
“On March 27, 2024, Metagenomi, Inc. announced its financial results for the year ended December 31, 2023 and additional business updates.”
Metagenomi Therapeutics, Inc.: Amended and restated bylaws to eliminate stockholder written consent and special meeting ability, establish advance notice procedures for stockholder proposals and director nominations, and conform to the restated certificate.
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders to become effective immediately upon effectiveness of the Registration Statement, became effective.”
Metagenomi Therapeutics, Inc.: Filed amended and restated certificate of incorporation to authorize 500,000,000 shares of common stock, eliminate references to existing preferred stock, and authorize 10,000,000 shares of undesignated preferred stock.
“the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.